Hidradenitis Suppurativa and Maternal and Offspring Outcomes.

IF 11.5 1区医学 Q1 DERMATOLOGY

JAMA dermatology Pub Date : 2024-10-16 DOI:10.1001/jamadermatol.2024.3584

Kaiyang Li, Vincent Piguet, David Croitoru, Shu Qin Wei, Émilie Brousseau, Elizabeth O'Brien, Nathalie Auger

{"title":"Hidradenitis Suppurativa and Maternal and Offspring Outcomes.","authors":"Kaiyang Li, Vincent Piguet, David Croitoru, Shu Qin Wei, Émilie Brousseau, Elizabeth O'Brien, Nathalie Auger","doi":"10.1001/jamadermatol.2024.3584","DOIUrl":null,"url":null,"abstract":"Importance: Hidradenitis suppurativa (HS) is associated with morbidity in persons of reproductive age, but the effect on maternal and offspring outcomes is understudied.Objective: To determine the association of HS with pregnancy outcomes and maternal and child morbidity in the long term.Design, setting, and participants: This population-based longitudinal cohort study with up to 16 years of follow-up took place between 2006 and 2022 in Quebec, Canada. .Exposure: Maternal HS.Main outcomes and measures: Outcomes included hypertensive disorders of pregnancy, gestational diabetes, and other birth outcomes as well as the long-term risk of hospitalization up to 16 years after delivery. The study used adjusted log-binomial and Cox proportional hazards regression models to estimate the association between maternal HS and pregnancy outcomes or hospitalization following pregnancy. Outcomes in both mothers and offspring were assessed.Results: There were 1 324 488 deliveries during the study, including 1332 (0.1%) among mothers with HS. Compared with patients without HS, patients with HS had a greater risk of hypertensive disorders of pregnancy (risk ratio [RR], 1.55 [95% CI, 1.29-1.87]), gestational diabetes (RR, 1.61 [95% CI, 1.40-1.85]), and severe maternal morbidity (RR, 1.38 [95% CI, 1.03-1.84]). In neonates, maternal HS was associated with risk of preterm birth (RR, 1.28 [95% CI, 1.07-1.53]) and birth defects (RR, 1.29 [95% CI, 1.07-1.56]). In the long term, HS was associated with 2.29 times the risk of maternal hospitalization (95% CI, 2.07-2.55) and 1.31 times the risk of childhood hospitalization (95% CI, 1.18-1.45), including hospitalization for respiratory, metabolic, psychiatric, and immune-related morbidity over time.Conclusions and relevance: This cohort study found that HS is associated with adverse maternal and offspring outcomes in the peripartum period and in the long term. Early detection and management of HS may help mitigate these outcomes.","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581566/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamadermatol.2024.3584","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Importance: Hidradenitis suppurativa (HS) is associated with morbidity in persons of reproductive age, but the effect on maternal and offspring outcomes is understudied.

Objective: To determine the association of HS with pregnancy outcomes and maternal and child morbidity in the long term.

Design, setting, and participants: This population-based longitudinal cohort study with up to 16 years of follow-up took place between 2006 and 2022 in Quebec, Canada. .

Exposure: Maternal HS.

Main outcomes and measures: Outcomes included hypertensive disorders of pregnancy, gestational diabetes, and other birth outcomes as well as the long-term risk of hospitalization up to 16 years after delivery. The study used adjusted log-binomial and Cox proportional hazards regression models to estimate the association between maternal HS and pregnancy outcomes or hospitalization following pregnancy. Outcomes in both mothers and offspring were assessed.

Results: There were 1 324 488 deliveries during the study, including 1332 (0.1%) among mothers with HS. Compared with patients without HS, patients with HS had a greater risk of hypertensive disorders of pregnancy (risk ratio [RR], 1.55 [95% CI, 1.29-1.87]), gestational diabetes (RR, 1.61 [95% CI, 1.40-1.85]), and severe maternal morbidity (RR, 1.38 [95% CI, 1.03-1.84]). In neonates, maternal HS was associated with risk of preterm birth (RR, 1.28 [95% CI, 1.07-1.53]) and birth defects (RR, 1.29 [95% CI, 1.07-1.56]). In the long term, HS was associated with 2.29 times the risk of maternal hospitalization (95% CI, 2.07-2.55) and 1.31 times the risk of childhood hospitalization (95% CI, 1.18-1.45), including hospitalization for respiratory, metabolic, psychiatric, and immune-related morbidity over time.

Conclusions and relevance: This cohort study found that HS is associated with adverse maternal and offspring outcomes in the peripartum period and in the long term. Early detection and management of HS may help mitigate these outcomes.

查看原文本刊更多论文

化脓性扁桃体炎与母婴结局

重要性：化脓性扁桃体炎（HS）与育龄人群的发病率有关，但其对母婴结局的影响尚未得到充分研究：目的：确定HS与妊娠结局及母婴长期发病率的关系：这项以人口为基础的纵向队列研究于 2006 年至 2022 年在加拿大魁北克省进行，随访时间长达 16 年。.暴露：产妇高血压：结果包括妊娠高血压疾病、妊娠糖尿病、其他分娩结果以及产后 16 年内的长期住院风险。研究采用调整后的对数二项式和考克斯比例危险回归模型来估算母亲妊娠高血压与妊娠结局或妊娠后住院之间的关系。对母亲和后代的结果进行了评估：研究期间共有 1 324 488 例分娩，其中 1332 例（0.1%）的母亲患有 HS。与非 HS 患者相比，HS 患者发生妊娠高血压疾病（风险比 [RR]，1.55 [95% CI，1.29-1.87]）、妊娠糖尿病（RR，1.61 [95% CI，1.40-1.85]）和严重孕产妇发病率（RR，1.38 [95% CI，1.03-1.84]）的风险更高。在新生儿中，产妇 HS 与早产风险（RR，1.28 [95% CI，1.07-1.53]）和出生缺陷（RR，1.29 [95% CI，1.07-1.56]）相关。从长期来看，HS 与孕产妇住院风险的 2.29 倍（95% CI，2.07-2.55）和儿童住院风险的 1.31 倍（95% CI，1.18-1.45）相关，包括随着时间的推移因呼吸系统、代谢、精神和免疫相关疾病住院：这项队列研究发现，HS 与围产期和长期的不良母婴结局有关。早期发现和治疗 HS 可能有助于减轻这些后果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JAMA dermatology DERMATOLOGY-

CiteScore

14.10

自引率

5.50%

发文量

300

期刊介绍： JAMA Dermatology is an international peer-reviewed journal that has been in continuous publication since 1882. It began publication by the American Medical Association in 1920 as Archives of Dermatology and Syphilology. The journal publishes material that helps in the development and testing of the effectiveness of diagnosis and treatment in medical and surgical dermatology, pediatric and geriatric dermatology, and oncologic and aesthetic dermatologic surgery. JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. It is published online weekly, every Wednesday, and in 12 print/online issues a year. The mission of the journal is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, with the aim of enabling dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care. The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. It also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists, aiming to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists. JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing.